Europe
Unique feature of bioSens-All™ technology enables discovery of therapeutics for pathologies linked to GPCR mistrafficking
“We have successfully engineered a new molecule, which is a modified sugar that shows broad-spectrum antiviral properties,” said Samuel Jones, from The University of Manchester.
“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.
The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.
RauCon has now introduced limits to the number of participants of its euroPLX and asiaPLX Pharma Partnering Conferences in order to increase their value for the individual participant.
PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.
Hypha Discovery Limited, the leading specialist CRO for drug metabolite provision, and Cypex Limited, experts in the provision of recombinant xenobiotic metabolising enzymes, have formed a partnership wherein Hypha can scale-up and purify metabolites made by Cypex enzymes.
Polarean Imaging plc announces that Jonathan Allis, Non-Executive Director, has assumed the role of Chairman with immediate effect.
GENOMICA, a wholly owned company of PharmaMar Group, is developing a kit to reliably detect and identify the new virus known as “Wuhan pneumonia”.
Evotec SE announced that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.
PRESS RELEASES